Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
3.420
-0.240 (-6.56%)
At close: Feb 27, 2026, 4:00 PM EST
3.400
-0.020 (-0.58%)
After-hours: Feb 27, 2026, 7:59 PM EST
Ironwood Pharmaceuticals Revenue
In the year 2025, Ironwood Pharmaceuticals had annual revenue of $296.15M, down -15.72%. Ironwood Pharmaceuticals had revenue of $47.71M in the quarter ending December 31, 2025, a decrease of -47.31%.
Revenue (ttm)
$296.15M
Revenue Growth
-15.72%
P/S Ratio
1.88
Revenue / Employee
$1,170,557
Employees
253
Market Cap
557.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 296.15M | -55.26M | -15.72% |
| Dec 31, 2024 | 351.41M | -91.33M | -20.63% |
| Dec 31, 2023 | 442.74M | 32.14M | 7.83% |
| Dec 31, 2022 | 410.60M | -3.16M | -0.76% |
| Dec 31, 2021 | 413.75M | 24.23M | 6.22% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 837.32M |
| Emergent BioSolutions | 788.90M |
| Organogenesis Holdings | 465.22M |
| Esperion Therapeutics | 303.80M |
| Akebia Therapeutics | 225.07M |
| Canopy Growth | 203.04M |
| Kamada | 174.79M |
| SIGA Technologies | 172.25M |
IRWD News
- 2 days ago - Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide - Seeking Alpha
- 3 days ago - Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook - Business Wire
- 10 days ago - Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call - Business Wire
- 2 months ago - Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance - Business Wire
- 3 months ago - Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025 - Seeking Alpha
- 3 months ago - Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance - Business Wire
- 4 months ago - Ironwood Stair & Rail Inc. Recognised With 2025 Consumer Choice Award for Stairs and Railings in Southern Alberta - Accesswire